Product Description
Mechanisms of Action: IL4A Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shanghai Maiji Biotechnology Co., Ltd./Baochuan Biomedical Technology (Shanghai) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prurigo
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20252190 |
CTR20252190 | P1 |
Completed |
Dermatitis, Atopic |
2025-10-06 |
2025-10-21 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232822 |
CTR20232822 | P1 |
Completed |
Dermatitis, Atopic |
2024-03-14 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20221766 |
CTR20221766 | P2 |
Completed |
Dermatitis, Atopic |
2023-09-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252129 |
CTR20252129 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
None |
2025-10-05 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20244735 |
CTR20244735 | P3 |
Active, not recruiting |
Prurigo |
None |
2025-11-02 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/30/2025 |
News Article |
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China |
|
08/19/2025 |
News Article |
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
|
02/21/2025 |
News Article |
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10 |
|
01/24/2025 |
News Article |
China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10 |